Indeed, inhibition of SLC25A11 in glioblastoma cells resulted in reduced cell viability, energy depletion, and mitochondrial dysfunction (Fig. 1d–g), highlighting the potential of targeting this gene as a therapeutic strategy for MAS inhibition in GBM treatment. The gene discussed is MAS1; the disease is glioblastoma.